The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
https://www.fda.gov/NewsEvents/Newsr..._source=Eloqua
https://www.fda.gov/NewsEvents/Newsr..._source=Eloqua
Comment